nodes	percent_of_prediction	percent_of_DWPC	metapath
Valproic Acid—UGT1A6—Mycophenolic acid—systemic scleroderma	0.173	0.226	CbGbCtD
Valproic Acid—UGT1A10—Mycophenolate mofetil—systemic scleroderma	0.112	0.146	CbGbCtD
Valproic Acid—UGT1A8—Mycophenolate mofetil—systemic scleroderma	0.112	0.146	CbGbCtD
Valproic Acid—UGT1A6—Mycophenolate mofetil—systemic scleroderma	0.0966	0.127	CbGbCtD
Valproic Acid—UGT1A9—Mycophenolic acid—systemic scleroderma	0.0504	0.066	CbGbCtD
Valproic Acid—UGT2B7—Mycophenolic acid—systemic scleroderma	0.0477	0.0625	CbGbCtD
Valproic Acid—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.0282	0.0369	CbGbCtD
Valproic Acid—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.0266	0.0349	CbGbCtD
Valproic Acid—SLC16A1—Methotrexate—systemic scleroderma	0.0197	0.0258	CbGbCtD
Valproic Acid—CYP2C8—Mometasone—systemic scleroderma	0.017	0.0222	CbGbCtD
Valproic Acid—SLC22A6—Captopril—systemic scleroderma	0.013	0.0171	CbGbCtD
Valproic Acid—SLC22A7—Methotrexate—systemic scleroderma	0.00967	0.0127	CbGbCtD
Valproic Acid—CYP1A2—Pentoxifylline—systemic scleroderma	0.00886	0.0116	CbGbCtD
Valproic Acid—CYP1A2—Leflunomide—systemic scleroderma	0.00846	0.0111	CbGbCtD
Valproic Acid—CYP2C9—Leflunomide—systemic scleroderma	0.00762	0.00998	CbGbCtD
Valproic Acid—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.00702	0.0092	CbGbCtD
Valproic Acid—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.00675	0.00884	CbGbCtD
Valproic Acid—CYP2C9—cardial valve—systemic scleroderma	0.00598	0.135	CbGeAlD
Valproic Acid—SLC22A8—Methotrexate—systemic scleroderma	0.0059	0.00773	CbGbCtD
Valproic Acid—CYP2C19—Prednisone—systemic scleroderma	0.00453	0.00593	CbGbCtD
Valproic Acid—SLC22A6—Methotrexate—systemic scleroderma	0.00411	0.00539	CbGbCtD
Valproic Acid—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00274	0.00359	CbGbCtD
Valproic Acid—HDAC2—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00248	1	CbGdCrCtD
Valproic Acid—CYP3A4—Prednisone—systemic scleroderma	0.00219	0.00287	CbGbCtD
Valproic Acid—OGDH—connective tissue—systemic scleroderma	0.00182	0.041	CbGeAlD
Valproic Acid—UGT1A10—digestive system—systemic scleroderma	0.00179	0.0403	CbGeAlD
Valproic Acid—UGT1A6—digestive system—systemic scleroderma	0.00166	0.0375	CbGeAlD
Valproic Acid—UGT1A8—digestive system—systemic scleroderma	0.00141	0.0319	CbGeAlD
Valproic Acid—OGDH—digestive system—systemic scleroderma	0.00132	0.0296	CbGeAlD
Valproic Acid—UGT1A3—digestive system—systemic scleroderma	0.00126	0.0284	CbGeAlD
Valproic Acid—OGDH—tendon—systemic scleroderma	0.00125	0.0282	CbGeAlD
Valproic Acid—UGT2B15—digestive system—systemic scleroderma	0.00119	0.0267	CbGeAlD
Valproic Acid—HDAC9—tendon—systemic scleroderma	0.0011	0.0249	CbGeAlD
Valproic Acid—OGDH—lung—systemic scleroderma	0.0011	0.0248	CbGeAlD
Valproic Acid—UGT1A4—digestive system—systemic scleroderma	0.00107	0.0242	CbGeAlD
Valproic Acid—ACADSB—digestive system—systemic scleroderma	0.00104	0.0235	CbGeAlD
Valproic Acid—ACADSB—tendon—systemic scleroderma	0.000994	0.0224	CbGeAlD
Valproic Acid—HDAC9—lung—systemic scleroderma	0.000968	0.0218	CbGeAlD
Valproic Acid—UGT1A9—digestive system—systemic scleroderma	0.000899	0.0202	CbGeAlD
Valproic Acid—ALDH5A1—tendon—systemic scleroderma	0.000875	0.0197	CbGeAlD
Valproic Acid—ACADSB—lung—systemic scleroderma	0.000873	0.0197	CbGeAlD
Valproic Acid—HDAC2—connective tissue—systemic scleroderma	0.000821	0.0185	CbGeAlD
Valproic Acid—PTGS1—artery—systemic scleroderma	0.000819	0.0185	CbGeAlD
Valproic Acid—CYP2C18—digestive system—systemic scleroderma	0.000785	0.0177	CbGeAlD
Valproic Acid—ALDH5A1—lung—systemic scleroderma	0.000768	0.0173	CbGeAlD
Valproic Acid—HDAC2—smooth muscle tissue—systemic scleroderma	0.000751	0.0169	CbGeAlD
Valproic Acid—ABAT—tendon—systemic scleroderma	0.000749	0.0169	CbGeAlD
Valproic Acid—HDAC2—skin of body—systemic scleroderma	0.000741	0.0167	CbGeAlD
Valproic Acid—UGT2B7—digestive system—systemic scleroderma	0.000724	0.0163	CbGeAlD
Valproic Acid—PTGS1—endothelium—systemic scleroderma	0.000692	0.0156	CbGeAlD
Valproic Acid—SLC22A7—digestive system—systemic scleroderma	0.000689	0.0155	CbGeAlD
Valproic Acid—ABAT—lung—systemic scleroderma	0.000657	0.0148	CbGeAlD
Valproic Acid—PTGS1—blood vessel—systemic scleroderma	0.000638	0.0144	CbGeAlD
Valproic Acid—HDAC2—digestive system—systemic scleroderma	0.000593	0.0134	CbGeAlD
Valproic Acid—HDAC2—tendon—systemic scleroderma	0.000564	0.0127	CbGeAlD
Valproic Acid—SLC16A1—digestive system—systemic scleroderma	0.000527	0.0119	CbGeAlD
Valproic Acid—SLC16A1—tendon—systemic scleroderma	0.000501	0.0113	CbGeAlD
Valproic Acid—HDAC2—lung—systemic scleroderma	0.000495	0.0112	CbGeAlD
Valproic Acid—SLC16A1—lung—systemic scleroderma	0.00044	0.00991	CbGeAlD
Valproic Acid—CYP2A6—lung—systemic scleroderma	0.000434	0.00977	CbGeAlD
Valproic Acid—SLC22A5—skin of body—systemic scleroderma	0.000376	0.00848	CbGeAlD
Valproic Acid—CYP2C19—digestive system—systemic scleroderma	0.000334	0.00752	CbGeAlD
Valproic Acid—PTGS1—connective tissue—systemic scleroderma	0.000327	0.00737	CbGeAlD
Valproic Acid—CYP2B6—skin of body—systemic scleroderma	0.000327	0.00736	CbGeAlD
Valproic Acid—SLC22A5—digestive system—systemic scleroderma	0.000301	0.00678	CbGeAlD
Valproic Acid—PTGS1—smooth muscle tissue—systemic scleroderma	0.000299	0.00674	CbGeAlD
Valproic Acid—PTGS1—skin of body—systemic scleroderma	0.000295	0.00666	CbGeAlD
Valproic Acid—SLC22A5—tendon—systemic scleroderma	0.000286	0.00646	CbGeAlD
Valproic Acid—CYP1A2—digestive system—systemic scleroderma	0.000273	0.00614	CbGeAlD
Valproic Acid—CYP3A5—digestive system—systemic scleroderma	0.000263	0.00593	CbGeAlD
Valproic Acid—CYP2B6—digestive system—systemic scleroderma	0.000261	0.00589	CbGeAlD
Valproic Acid—CYP2C9—digestive system—systemic scleroderma	0.000259	0.00583	CbGeAlD
Valproic Acid—SLC22A5—lung—systemic scleroderma	0.000251	0.00566	CbGeAlD
Valproic Acid—PTGS1—digestive system—systemic scleroderma	0.000236	0.00532	CbGeAlD
Valproic Acid—CYP1A2—lung—systemic scleroderma	0.000228	0.00513	CbGeAlD
Valproic Acid—PTGS1—tendon—systemic scleroderma	0.000225	0.00507	CbGeAlD
Valproic Acid—CYP3A5—lung—systemic scleroderma	0.00022	0.00495	CbGeAlD
Valproic Acid—CYP2B6—lung—systemic scleroderma	0.000218	0.00492	CbGeAlD
Valproic Acid—CYP3A4—digestive system—systemic scleroderma	0.000197	0.00445	CbGeAlD
Valproic Acid—PTGS1—lung—systemic scleroderma	0.000197	0.00445	CbGeAlD
Valproic Acid—Hypotension—Lisinopril—systemic scleroderma	7.92e-05	0.000417	CcSEcCtD
Valproic Acid—Dizziness—Captopril—systemic scleroderma	7.92e-05	0.000417	CcSEcCtD
Valproic Acid—Depression—Prednisone—systemic scleroderma	7.87e-05	0.000415	CcSEcCtD
Valproic Acid—Hypertension—Mycophenolate mofetil—systemic scleroderma	7.86e-05	0.000414	CcSEcCtD
Valproic Acid—Urticaria—Leflunomide—systemic scleroderma	7.84e-05	0.000413	CcSEcCtD
Valproic Acid—Abdominal pain—Leflunomide—systemic scleroderma	7.8e-05	0.000411	CcSEcCtD
Valproic Acid—Body temperature increased—Leflunomide—systemic scleroderma	7.8e-05	0.000411	CcSEcCtD
Valproic Acid—Feeling abnormal—Mycophenolic acid—systemic scleroderma	7.76e-05	0.000409	CcSEcCtD
Valproic Acid—Myalgia—Mycophenolate mofetil—systemic scleroderma	7.75e-05	0.000408	CcSEcCtD
Valproic Acid—Arthralgia—Mycophenolate mofetil—systemic scleroderma	7.75e-05	0.000408	CcSEcCtD
Valproic Acid—Chest pain—Mycophenolate mofetil—systemic scleroderma	7.75e-05	0.000408	CcSEcCtD
Valproic Acid—Breast disorder—Methotrexate—systemic scleroderma	7.74e-05	0.000408	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	7.73e-05	0.000407	CcSEcCtD
Valproic Acid—Anxiety—Mycophenolate mofetil—systemic scleroderma	7.72e-05	0.000407	CcSEcCtD
Valproic Acid—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	7.71e-05	0.000406	CcSEcCtD
Valproic Acid—Hypersensitivity—Azathioprine—systemic scleroderma	7.7e-05	0.000406	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	7.7e-05	0.000406	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	7.7e-05	0.000405	CcSEcCtD
Valproic Acid—Insomnia—Lisinopril—systemic scleroderma	7.67e-05	0.000404	CcSEcCtD
Valproic Acid—Discomfort—Mycophenolate mofetil—systemic scleroderma	7.66e-05	0.000403	CcSEcCtD
Valproic Acid—Paraesthesia—Lisinopril—systemic scleroderma	7.61e-05	0.000401	CcSEcCtD
Valproic Acid—Vomiting—Captopril—systemic scleroderma	7.61e-05	0.000401	CcSEcCtD
Valproic Acid—Dry mouth—Mycophenolate mofetil—systemic scleroderma	7.58e-05	0.000399	CcSEcCtD
Valproic Acid—Dyspnoea—Lisinopril—systemic scleroderma	7.56e-05	0.000398	CcSEcCtD
Valproic Acid—Rash—Captopril—systemic scleroderma	7.55e-05	0.000398	CcSEcCtD
Valproic Acid—Dermatitis—Captopril—systemic scleroderma	7.54e-05	0.000397	CcSEcCtD
Valproic Acid—Somnolence—Lisinopril—systemic scleroderma	7.54e-05	0.000397	CcSEcCtD
Valproic Acid—Headache—Captopril—systemic scleroderma	7.5e-05	0.000395	CcSEcCtD
Valproic Acid—Confusional state—Mycophenolate mofetil—systemic scleroderma	7.49e-05	0.000395	CcSEcCtD
Valproic Acid—Dyspepsia—Lisinopril—systemic scleroderma	7.46e-05	0.000393	CcSEcCtD
Valproic Acid—Body temperature increased—Mycophenolic acid—systemic scleroderma	7.44e-05	0.000392	CcSEcCtD
Valproic Acid—Abdominal pain—Mycophenolic acid—systemic scleroderma	7.44e-05	0.000392	CcSEcCtD
Valproic Acid—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	7.43e-05	0.000391	CcSEcCtD
Valproic Acid—Oedema—Mycophenolate mofetil—systemic scleroderma	7.43e-05	0.000391	CcSEcCtD
Valproic Acid—Infection—Mycophenolate mofetil—systemic scleroderma	7.38e-05	0.000389	CcSEcCtD
Valproic Acid—Decreased appetite—Lisinopril—systemic scleroderma	7.37e-05	0.000388	CcSEcCtD
Valproic Acid—Eosinophilia—Methotrexate—systemic scleroderma	7.33e-05	0.000386	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Lisinopril—systemic scleroderma	7.32e-05	0.000386	CcSEcCtD
Valproic Acid—Fatigue—Lisinopril—systemic scleroderma	7.31e-05	0.000385	CcSEcCtD
Valproic Acid—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	7.29e-05	0.000384	CcSEcCtD
Valproic Acid—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	7.27e-05	0.000383	CcSEcCtD
Valproic Acid—Hypersensitivity—Leflunomide—systemic scleroderma	7.27e-05	0.000383	CcSEcCtD
Valproic Acid—Pancreatitis—Methotrexate—systemic scleroderma	7.26e-05	0.000382	CcSEcCtD
Valproic Acid—Constipation—Lisinopril—systemic scleroderma	7.25e-05	0.000382	CcSEcCtD
Valproic Acid—Pain—Lisinopril—systemic scleroderma	7.25e-05	0.000382	CcSEcCtD
Valproic Acid—Tachycardia—Mycophenolate mofetil—systemic scleroderma	7.25e-05	0.000382	CcSEcCtD
Valproic Acid—Skin disorder—Mycophenolate mofetil—systemic scleroderma	7.22e-05	0.00038	CcSEcCtD
Valproic Acid—Bradycardia—Prednisone—systemic scleroderma	7.22e-05	0.00038	CcSEcCtD
Valproic Acid—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	7.18e-05	0.000378	CcSEcCtD
Valproic Acid—Diarrhoea—Azathioprine—systemic scleroderma	7.15e-05	0.000377	CcSEcCtD
Valproic Acid—Haemoglobin—Prednisone—systemic scleroderma	7.12e-05	0.000375	CcSEcCtD
Valproic Acid—Nausea—Captopril—systemic scleroderma	7.11e-05	0.000375	CcSEcCtD
Valproic Acid—Abdominal discomfort—Methotrexate—systemic scleroderma	7.1e-05	0.000374	CcSEcCtD
Valproic Acid—Haemorrhage—Prednisone—systemic scleroderma	7.09e-05	0.000373	CcSEcCtD
Valproic Acid—Anorexia—Mycophenolate mofetil—systemic scleroderma	7.08e-05	0.000373	CcSEcCtD
Valproic Acid—Asthenia—Leflunomide—systemic scleroderma	7.08e-05	0.000373	CcSEcCtD
Valproic Acid—Hallucination—Prednisone—systemic scleroderma	7.05e-05	0.000372	CcSEcCtD
Valproic Acid—Pancytopenia—Methotrexate—systemic scleroderma	7.03e-05	0.00037	CcSEcCtD
Valproic Acid—Feeling abnormal—Lisinopril—systemic scleroderma	6.99e-05	0.000368	CcSEcCtD
Valproic Acid—Pruritus—Leflunomide—systemic scleroderma	6.98e-05	0.000368	CcSEcCtD
Valproic Acid—Connective tissue disorder—Prednisone—systemic scleroderma	6.97e-05	0.000367	CcSEcCtD
Valproic Acid—Hypotension—Mycophenolate mofetil—systemic scleroderma	6.94e-05	0.000366	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Lisinopril—systemic scleroderma	6.93e-05	0.000365	CcSEcCtD
Valproic Acid—Neutropenia—Methotrexate—systemic scleroderma	6.92e-05	0.000365	CcSEcCtD
Valproic Acid—Dysuria—Methotrexate—systemic scleroderma	6.92e-05	0.000365	CcSEcCtD
Valproic Acid—Dizziness—Azathioprine—systemic scleroderma	6.91e-05	0.000364	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	6.77e-05	0.000357	CcSEcCtD
Valproic Acid—Photosensitivity reaction—Methotrexate—systemic scleroderma	6.76e-05	0.000356	CcSEcCtD
Valproic Acid—Asthenia—Mycophenolic acid—systemic scleroderma	6.75e-05	0.000356	CcSEcCtD
Valproic Acid—Diarrhoea—Leflunomide—systemic scleroderma	6.75e-05	0.000356	CcSEcCtD
Valproic Acid—Urticaria—Lisinopril—systemic scleroderma	6.74e-05	0.000355	CcSEcCtD
Valproic Acid—Insomnia—Mycophenolate mofetil—systemic scleroderma	6.72e-05	0.000354	CcSEcCtD
Valproic Acid—Abdominal pain—Lisinopril—systemic scleroderma	6.7e-05	0.000353	CcSEcCtD
Valproic Acid—Body temperature increased—Lisinopril—systemic scleroderma	6.7e-05	0.000353	CcSEcCtD
Valproic Acid—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	6.67e-05	0.000351	CcSEcCtD
Valproic Acid—Pruritus—Mycophenolic acid—systemic scleroderma	6.66e-05	0.000351	CcSEcCtD
Valproic Acid—Vomiting—Azathioprine—systemic scleroderma	6.64e-05	0.00035	CcSEcCtD
Valproic Acid—Pneumonia—Methotrexate—systemic scleroderma	6.64e-05	0.00035	CcSEcCtD
Valproic Acid—Eye disorder—Prednisone—systemic scleroderma	6.62e-05	0.000349	CcSEcCtD
Valproic Acid—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	6.62e-05	0.000349	CcSEcCtD
Valproic Acid—Somnolence—Mycophenolate mofetil—systemic scleroderma	6.6e-05	0.000348	CcSEcCtD
Valproic Acid—Drowsiness—Methotrexate—systemic scleroderma	6.6e-05	0.000348	CcSEcCtD
Valproic Acid—Rash—Azathioprine—systemic scleroderma	6.59e-05	0.000347	CcSEcCtD
Valproic Acid—Dermatitis—Azathioprine—systemic scleroderma	6.58e-05	0.000347	CcSEcCtD
Valproic Acid—Depression—Methotrexate—systemic scleroderma	6.58e-05	0.000347	CcSEcCtD
Valproic Acid—Headache—Azathioprine—systemic scleroderma	6.55e-05	0.000345	CcSEcCtD
Valproic Acid—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	6.54e-05	0.000345	CcSEcCtD
Valproic Acid—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	6.54e-05	0.000345	CcSEcCtD
Valproic Acid—Dizziness—Leflunomide—systemic scleroderma	6.53e-05	0.000344	CcSEcCtD
Valproic Acid—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	6.46e-05	0.00034	CcSEcCtD
Valproic Acid—Diarrhoea—Mycophenolic acid—systemic scleroderma	6.44e-05	0.000339	CcSEcCtD
Valproic Acid—Stomatitis—Methotrexate—systemic scleroderma	6.43e-05	0.000339	CcSEcCtD
Valproic Acid—Angiopathy—Prednisone—systemic scleroderma	6.43e-05	0.000339	CcSEcCtD
Valproic Acid—Conjunctivitis—Methotrexate—systemic scleroderma	6.41e-05	0.000338	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	6.41e-05	0.000338	CcSEcCtD
Valproic Acid—Immune system disorder—Prednisone—systemic scleroderma	6.4e-05	0.000337	CcSEcCtD
Valproic Acid—Constipation—Mycophenolate mofetil—systemic scleroderma	6.35e-05	0.000335	CcSEcCtD
Valproic Acid—Pain—Mycophenolate mofetil—systemic scleroderma	6.35e-05	0.000335	CcSEcCtD
Valproic Acid—Arrhythmia—Prednisone—systemic scleroderma	6.33e-05	0.000334	CcSEcCtD
Valproic Acid—Sweating—Methotrexate—systemic scleroderma	6.33e-05	0.000333	CcSEcCtD
Valproic Acid—Vomiting—Leflunomide—systemic scleroderma	6.27e-05	0.000331	CcSEcCtD
Valproic Acid—Alopecia—Prednisone—systemic scleroderma	6.26e-05	0.00033	CcSEcCtD
Valproic Acid—Hypersensitivity—Lisinopril—systemic scleroderma	6.25e-05	0.000329	CcSEcCtD
Valproic Acid—Hepatobiliary disease—Methotrexate—systemic scleroderma	6.24e-05	0.000329	CcSEcCtD
Valproic Acid—Dizziness—Mycophenolic acid—systemic scleroderma	6.23e-05	0.000328	CcSEcCtD
Valproic Acid—Epistaxis—Methotrexate—systemic scleroderma	6.22e-05	0.000328	CcSEcCtD
Valproic Acid—Rash—Leflunomide—systemic scleroderma	6.22e-05	0.000328	CcSEcCtD
Valproic Acid—Dermatitis—Leflunomide—systemic scleroderma	6.22e-05	0.000327	CcSEcCtD
Valproic Acid—Mental disorder—Prednisone—systemic scleroderma	6.21e-05	0.000327	CcSEcCtD
Valproic Acid—Nausea—Azathioprine—systemic scleroderma	6.21e-05	0.000327	CcSEcCtD
Valproic Acid—Headache—Leflunomide—systemic scleroderma	6.18e-05	0.000326	CcSEcCtD
Valproic Acid—Malnutrition—Prednisone—systemic scleroderma	6.17e-05	0.000325	CcSEcCtD
Valproic Acid—Agranulocytosis—Methotrexate—systemic scleroderma	6.16e-05	0.000324	CcSEcCtD
Valproic Acid—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	6.12e-05	0.000323	CcSEcCtD
Valproic Acid—Asthenia—Lisinopril—systemic scleroderma	6.08e-05	0.00032	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	6.08e-05	0.00032	CcSEcCtD
Valproic Acid—Pruritus—Lisinopril—systemic scleroderma	6e-05	0.000316	CcSEcCtD
Valproic Acid—Vomiting—Mycophenolic acid—systemic scleroderma	5.99e-05	0.000315	CcSEcCtD
Valproic Acid—Haemoglobin—Methotrexate—systemic scleroderma	5.95e-05	0.000314	CcSEcCtD
Valproic Acid—Rash—Mycophenolic acid—systemic scleroderma	5.94e-05	0.000313	CcSEcCtD
Valproic Acid—Dermatitis—Mycophenolic acid—systemic scleroderma	5.93e-05	0.000312	CcSEcCtD
Valproic Acid—Haemorrhage—Methotrexate—systemic scleroderma	5.92e-05	0.000312	CcSEcCtD
Valproic Acid—Urticaria—Mycophenolate mofetil—systemic scleroderma	5.9e-05	0.000311	CcSEcCtD
Valproic Acid—Headache—Mycophenolic acid—systemic scleroderma	5.9e-05	0.000311	CcSEcCtD
Valproic Acid—Pharyngitis—Methotrexate—systemic scleroderma	5.88e-05	0.00031	CcSEcCtD
Valproic Acid—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	5.87e-05	0.000309	CcSEcCtD
Valproic Acid—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	5.87e-05	0.000309	CcSEcCtD
Valproic Acid—Nausea—Leflunomide—systemic scleroderma	5.86e-05	0.000309	CcSEcCtD
Valproic Acid—Urinary tract disorder—Methotrexate—systemic scleroderma	5.85e-05	0.000308	CcSEcCtD
Valproic Acid—Vision blurred—Prednisone—systemic scleroderma	5.82e-05	0.000306	CcSEcCtD
Valproic Acid—Urethral disorder—Methotrexate—systemic scleroderma	5.81e-05	0.000306	CcSEcCtD
Valproic Acid—Diarrhoea—Lisinopril—systemic scleroderma	5.8e-05	0.000306	CcSEcCtD
Valproic Acid—Ill-defined disorder—Prednisone—systemic scleroderma	5.73e-05	0.000302	CcSEcCtD
Valproic Acid—Visual impairment—Methotrexate—systemic scleroderma	5.71e-05	0.000301	CcSEcCtD
Valproic Acid—Anaemia—Prednisone—systemic scleroderma	5.7e-05	0.0003	CcSEcCtD
Valproic Acid—Agitation—Prednisone—systemic scleroderma	5.67e-05	0.000299	CcSEcCtD
Valproic Acid—Angioedema—Prednisone—systemic scleroderma	5.64e-05	0.000297	CcSEcCtD
Valproic Acid—Dizziness—Lisinopril—systemic scleroderma	5.61e-05	0.000295	CcSEcCtD
Valproic Acid—Erythema multiforme—Methotrexate—systemic scleroderma	5.6e-05	0.000295	CcSEcCtD
Valproic Acid—Nausea—Mycophenolic acid—systemic scleroderma	5.59e-05	0.000295	CcSEcCtD
Valproic Acid—Malaise—Prednisone—systemic scleroderma	5.56e-05	0.000293	CcSEcCtD
Valproic Acid—Vertigo—Prednisone—systemic scleroderma	5.54e-05	0.000292	CcSEcCtD
Valproic Acid—Eye disorder—Methotrexate—systemic scleroderma	5.54e-05	0.000292	CcSEcCtD
Valproic Acid—Tinnitus—Methotrexate—systemic scleroderma	5.52e-05	0.000291	CcSEcCtD
Valproic Acid—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	5.47e-05	0.000288	CcSEcCtD
Valproic Acid—Vomiting—Lisinopril—systemic scleroderma	5.39e-05	0.000284	CcSEcCtD
Valproic Acid—Angiopathy—Methotrexate—systemic scleroderma	5.37e-05	0.000283	CcSEcCtD
Valproic Acid—Immune system disorder—Methotrexate—systemic scleroderma	5.35e-05	0.000282	CcSEcCtD
Valproic Acid—Rash—Lisinopril—systemic scleroderma	5.35e-05	0.000282	CcSEcCtD
Valproic Acid—Dermatitis—Lisinopril—systemic scleroderma	5.34e-05	0.000281	CcSEcCtD
Valproic Acid—Mediastinal disorder—Methotrexate—systemic scleroderma	5.34e-05	0.000281	CcSEcCtD
Valproic Acid—Asthenia—Mycophenolate mofetil—systemic scleroderma	5.33e-05	0.000281	CcSEcCtD
Valproic Acid—Hypertension—Prednisone—systemic scleroderma	5.33e-05	0.000281	CcSEcCtD
Valproic Acid—Chills—Methotrexate—systemic scleroderma	5.32e-05	0.00028	CcSEcCtD
Valproic Acid—Headache—Lisinopril—systemic scleroderma	5.31e-05	0.00028	CcSEcCtD
Valproic Acid—Pruritus—Mycophenolate mofetil—systemic scleroderma	5.26e-05	0.000277	CcSEcCtD
Valproic Acid—Myalgia—Prednisone—systemic scleroderma	5.25e-05	0.000277	CcSEcCtD
Valproic Acid—Arthralgia—Prednisone—systemic scleroderma	5.25e-05	0.000277	CcSEcCtD
Valproic Acid—Anxiety—Prednisone—systemic scleroderma	5.24e-05	0.000276	CcSEcCtD
Valproic Acid—Alopecia—Methotrexate—systemic scleroderma	5.23e-05	0.000276	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	5.22e-05	0.000275	CcSEcCtD
Valproic Acid—Discomfort—Prednisone—systemic scleroderma	5.19e-05	0.000273	CcSEcCtD
Valproic Acid—Mental disorder—Methotrexate—systemic scleroderma	5.19e-05	0.000273	CcSEcCtD
Valproic Acid—Malnutrition—Methotrexate—systemic scleroderma	5.16e-05	0.000272	CcSEcCtD
Valproic Acid—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	5.08e-05	0.000268	CcSEcCtD
Valproic Acid—Dysgeusia—Methotrexate—systemic scleroderma	5.05e-05	0.000266	CcSEcCtD
Valproic Acid—Nausea—Lisinopril—systemic scleroderma	5.04e-05	0.000265	CcSEcCtD
Valproic Acid—Anaphylactic shock—Prednisone—systemic scleroderma	5.04e-05	0.000265	CcSEcCtD
Valproic Acid—Oedema—Prednisone—systemic scleroderma	5.04e-05	0.000265	CcSEcCtD
Valproic Acid—Infection—Prednisone—systemic scleroderma	5e-05	0.000264	CcSEcCtD
Valproic Acid—Back pain—Methotrexate—systemic scleroderma	4.99e-05	0.000263	CcSEcCtD
Valproic Acid—Nervous system disorder—Prednisone—systemic scleroderma	4.94e-05	0.00026	CcSEcCtD
Valproic Acid—Tachycardia—Prednisone—systemic scleroderma	4.92e-05	0.000259	CcSEcCtD
Valproic Acid—Dizziness—Mycophenolate mofetil—systemic scleroderma	4.91e-05	0.000259	CcSEcCtD
Valproic Acid—Skin disorder—Prednisone—systemic scleroderma	4.89e-05	0.000258	CcSEcCtD
Valproic Acid—Hyperhidrosis—Prednisone—systemic scleroderma	4.87e-05	0.000256	CcSEcCtD
Valproic Acid—Vision blurred—Methotrexate—systemic scleroderma	4.86e-05	0.000256	CcSEcCtD
Valproic Acid—Anorexia—Prednisone—systemic scleroderma	4.8e-05	0.000253	CcSEcCtD
Valproic Acid—Ill-defined disorder—Methotrexate—systemic scleroderma	4.78e-05	0.000252	CcSEcCtD
Valproic Acid—Anaemia—Methotrexate—systemic scleroderma	4.77e-05	0.000251	CcSEcCtD
Valproic Acid—Vomiting—Mycophenolate mofetil—systemic scleroderma	4.72e-05	0.000249	CcSEcCtD
Valproic Acid—Rash—Mycophenolate mofetil—systemic scleroderma	4.68e-05	0.000247	CcSEcCtD
Valproic Acid—Dermatitis—Mycophenolate mofetil—systemic scleroderma	4.68e-05	0.000247	CcSEcCtD
Valproic Acid—Headache—Mycophenolate mofetil—systemic scleroderma	4.65e-05	0.000245	CcSEcCtD
Valproic Acid—Malaise—Methotrexate—systemic scleroderma	4.65e-05	0.000245	CcSEcCtD
Valproic Acid—Vertigo—Methotrexate—systemic scleroderma	4.63e-05	0.000244	CcSEcCtD
Valproic Acid—Leukopenia—Methotrexate—systemic scleroderma	4.62e-05	0.000243	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Prednisone—systemic scleroderma	4.59e-05	0.000242	CcSEcCtD
Valproic Acid—Insomnia—Prednisone—systemic scleroderma	4.55e-05	0.00024	CcSEcCtD
Valproic Acid—Paraesthesia—Prednisone—systemic scleroderma	4.52e-05	0.000238	CcSEcCtD
Valproic Acid—Cough—Methotrexate—systemic scleroderma	4.5e-05	0.000237	CcSEcCtD
Valproic Acid—Dyspepsia—Prednisone—systemic scleroderma	4.43e-05	0.000234	CcSEcCtD
Valproic Acid—Nausea—Mycophenolate mofetil—systemic scleroderma	4.41e-05	0.000232	CcSEcCtD
Valproic Acid—Chest pain—Methotrexate—systemic scleroderma	4.39e-05	0.000231	CcSEcCtD
Valproic Acid—Myalgia—Methotrexate—systemic scleroderma	4.39e-05	0.000231	CcSEcCtD
Valproic Acid—Arthralgia—Methotrexate—systemic scleroderma	4.39e-05	0.000231	CcSEcCtD
Valproic Acid—Decreased appetite—Prednisone—systemic scleroderma	4.38e-05	0.000231	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	4.36e-05	0.00023	CcSEcCtD
Valproic Acid—Fatigue—Prednisone—systemic scleroderma	4.34e-05	0.000229	CcSEcCtD
Valproic Acid—Discomfort—Methotrexate—systemic scleroderma	4.34e-05	0.000229	CcSEcCtD
Valproic Acid—Constipation—Prednisone—systemic scleroderma	4.31e-05	0.000227	CcSEcCtD
Valproic Acid—Confusional state—Methotrexate—systemic scleroderma	4.24e-05	0.000224	CcSEcCtD
Valproic Acid—Anaphylactic shock—Methotrexate—systemic scleroderma	4.21e-05	0.000222	CcSEcCtD
Valproic Acid—Infection—Methotrexate—systemic scleroderma	4.18e-05	0.00022	CcSEcCtD
Valproic Acid—Feeling abnormal—Prednisone—systemic scleroderma	4.15e-05	0.000219	CcSEcCtD
Valproic Acid—Nervous system disorder—Methotrexate—systemic scleroderma	4.13e-05	0.000217	CcSEcCtD
Valproic Acid—Thrombocytopenia—Methotrexate—systemic scleroderma	4.12e-05	0.000217	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Prednisone—systemic scleroderma	4.12e-05	0.000217	CcSEcCtD
Valproic Acid—Skin disorder—Methotrexate—systemic scleroderma	4.09e-05	0.000215	CcSEcCtD
Valproic Acid—Hyperhidrosis—Methotrexate—systemic scleroderma	4.07e-05	0.000214	CcSEcCtD
Valproic Acid—Anorexia—Methotrexate—systemic scleroderma	4.01e-05	0.000211	CcSEcCtD
Valproic Acid—Urticaria—Prednisone—systemic scleroderma	4e-05	0.000211	CcSEcCtD
Valproic Acid—Body temperature increased—Prednisone—systemic scleroderma	3.98e-05	0.00021	CcSEcCtD
Valproic Acid—Abdominal pain—Prednisone—systemic scleroderma	3.98e-05	0.00021	CcSEcCtD
Valproic Acid—Hypotension—Methotrexate—systemic scleroderma	3.93e-05	0.000207	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	3.83e-05	0.000202	CcSEcCtD
Valproic Acid—Insomnia—Methotrexate—systemic scleroderma	3.81e-05	0.000201	CcSEcCtD
Valproic Acid—Paraesthesia—Methotrexate—systemic scleroderma	3.78e-05	0.000199	CcSEcCtD
Valproic Acid—Dyspnoea—Methotrexate—systemic scleroderma	3.75e-05	0.000198	CcSEcCtD
Valproic Acid—Somnolence—Methotrexate—systemic scleroderma	3.74e-05	0.000197	CcSEcCtD
Valproic Acid—Hypersensitivity—Prednisone—systemic scleroderma	3.71e-05	0.000195	CcSEcCtD
Valproic Acid—Dyspepsia—Methotrexate—systemic scleroderma	3.7e-05	0.000195	CcSEcCtD
Valproic Acid—Decreased appetite—Methotrexate—systemic scleroderma	3.66e-05	0.000193	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Methotrexate—systemic scleroderma	3.63e-05	0.000191	CcSEcCtD
Valproic Acid—Fatigue—Methotrexate—systemic scleroderma	3.63e-05	0.000191	CcSEcCtD
Valproic Acid—Asthenia—Prednisone—systemic scleroderma	3.61e-05	0.00019	CcSEcCtD
Valproic Acid—Pain—Methotrexate—systemic scleroderma	3.6e-05	0.00019	CcSEcCtD
Valproic Acid—Pruritus—Prednisone—systemic scleroderma	3.56e-05	0.000188	CcSEcCtD
Valproic Acid—Feeling abnormal—Methotrexate—systemic scleroderma	3.47e-05	0.000183	CcSEcCtD
Valproic Acid—Diarrhoea—Prednisone—systemic scleroderma	3.45e-05	0.000182	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.44e-05	0.000181	CcSEcCtD
Valproic Acid—Urticaria—Methotrexate—systemic scleroderma	3.34e-05	0.000176	CcSEcCtD
Valproic Acid—Dizziness—Prednisone—systemic scleroderma	3.33e-05	0.000175	CcSEcCtD
Valproic Acid—Abdominal pain—Methotrexate—systemic scleroderma	3.33e-05	0.000175	CcSEcCtD
Valproic Acid—Body temperature increased—Methotrexate—systemic scleroderma	3.33e-05	0.000175	CcSEcCtD
Valproic Acid—Vomiting—Prednisone—systemic scleroderma	3.2e-05	0.000169	CcSEcCtD
Valproic Acid—Rash—Prednisone—systemic scleroderma	3.18e-05	0.000167	CcSEcCtD
Valproic Acid—Dermatitis—Prednisone—systemic scleroderma	3.17e-05	0.000167	CcSEcCtD
Valproic Acid—Headache—Prednisone—systemic scleroderma	3.15e-05	0.000166	CcSEcCtD
Valproic Acid—Hypersensitivity—Methotrexate—systemic scleroderma	3.1e-05	0.000163	CcSEcCtD
Valproic Acid—Asthenia—Methotrexate—systemic scleroderma	3.02e-05	0.000159	CcSEcCtD
Valproic Acid—Nausea—Prednisone—systemic scleroderma	2.99e-05	0.000158	CcSEcCtD
Valproic Acid—Pruritus—Methotrexate—systemic scleroderma	2.98e-05	0.000157	CcSEcCtD
Valproic Acid—Diarrhoea—Methotrexate—systemic scleroderma	2.88e-05	0.000152	CcSEcCtD
Valproic Acid—Dizziness—Methotrexate—systemic scleroderma	2.78e-05	0.000147	CcSEcCtD
Valproic Acid—Vomiting—Methotrexate—systemic scleroderma	2.68e-05	0.000141	CcSEcCtD
Valproic Acid—Rash—Methotrexate—systemic scleroderma	2.65e-05	0.00014	CcSEcCtD
Valproic Acid—Dermatitis—Methotrexate—systemic scleroderma	2.65e-05	0.00014	CcSEcCtD
Valproic Acid—Headache—Methotrexate—systemic scleroderma	2.64e-05	0.000139	CcSEcCtD
Valproic Acid—Nausea—Methotrexate—systemic scleroderma	2.5e-05	0.000132	CcSEcCtD
